Smoking associated with increased mortality among colorectal cancer survivors
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, American Cancer Society researchers have found that colorectal cancer survivors who smoke cigarettes are twice as likely to die compared with non-smoking survivors.
Existing evidence has shown that cigarette smoking is linked with increased all-cause mortality, increased colorectal cancer-specific mortality, and increased risk for developing colorectal cancer, but researchers sought to further investigate the association between smoking pre- and post-diagnosis and all-cause and colorectal cancer-specific mortality among survivors of colorectal cancer.
Researchers identified 2,548 patients with newly diagnosed invasive, non-metastatic colorectal cancer in the American Cancer Society's Cancer Prevention Study II. Of those, 1,074 died, including 453 due to colorectal cancer, during a mean follow-up duration of 7.5 years.
Results showed that patients who smoked pre-diagnosis were more than twice as likely to die from all causes and colorectal cancer. In addition, former smokers before diagnosis had a higher risk of dying from any cause, but not specifically colorectal cancer.
Researchers found that smoking post-diagnosis also doubled survivors' risk of all-cause mortality and colorectal cancer-specific mortality.
Colorectal cancer survivors who smoke cigarettes are twice as likely to die compared with non-smoking survivors.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|